All News

"To avoid unnecessary treatment, percutaneous biopsy of the small renal mass has increased for the past several years, but its use remains highly variable," writes Badar M. Mian, MD.

“Implementing Jelmyto earlier in real-world scenarios for LG-UTUC may offer appropriate low-risk patients the choice of minimal ablation or biopsy alone for renal preservation," says Hristos Z. Kaimakliotis, MD.

Smaller incision may lead to reduced postoperative pain for some patients.

Data showed a decrease in patient symptoms following Aquablation procedures, with an average IPSS of 22.6 at baseline compared with 6.8 at 5-year follow-up.

Patients receiving nivolumab plus cisplatin-based chemotherapy lived longer than patients treated with standard chemotherapy alone.

The minimally invasive surgical therapy is approved for the treatment of lower urinary tract symptoms secondary to BPH.

"One of the things that made a difference, at least in my practice, was one of the newer pulse modulated holmium lasers," says Smita De, MD, PhD.

“Our findings show that race-modified equations account for some but not all of the disparity in partial nephrectomy use. We need to keep searching for answers to ensure people of all races receive appropriate care," said Christopher Weight, MD.

"Our most significant finding may be that patients experience financial toxicity despite their ability to remain compliant with treatment," says Daniel D. Joyce, MD.

“This study truly changes the paradigm of infections and suggests we need to work smarter, not harder, to prevent infections,” said urologist Scott Lundy, MD, PhD.

"The fact that we are able to swab and look at these proteins means that we might be able to identify women at risk early on,” says Maria Florian-Rodriguez, MD.

"An attorney who just reads off a script spewing random facts at the jury will likely cause the jurors to check out," writes Kenton H. Steele, Esq.

A group of patients were shown to have an average of 6.3 cystitis episodes per year before administration of Lactobacillus, compared with 2.4 episodes after administration.

The study will assess the ability of Cu-64 SAR-bisPSMA to detect prostate cancer within the pelvic lymph nodes.

"Another thing is to customize your EHR with favorite orders and grouped orders, and these things can be standardized across a practice," says Sarah Hecht, MD.

Awardees are being recognized for creative approaches to accelerating progress in bladder cancer research.

“To our knowledge, these results are the first to suggest an association between second-generation [antiandrogens] and cognitive and functional toxic effects based on data from prospective [randomized controlled trials],” the investigators wrote.

UroMonitor was developed in response to conventional urodynamics, which have several limitations.

"The high reproducibility of reader results across all regions is clinically valuable, with the potential to influence patient management prior to surgery for patients with newly diagnosed disease," says Phillip H. Kuo, MD, PhD.

A response was observed in nearly two-thirds of cisplatin-ineligible patients with advanced urothelial cancer treated with enfortumab vedotin plus pembrolizumab in the first-line setting.

"Personalized dosing allowed one-third of the men in this study to have treatment breaks while still achieving the same progression-free and overall survival outcomes they would have if they received continuous treatment," says Andrew Nguyen, MBBS, FRACP, AANMS.

Researchers still urge caution when considering testosterone therapy.

The new space includes a clinical laboratory for IsoPSA testing, labs for research and development, offices, and manufacturing spaces for production and distribution of in vitro diagnostic kits.

Overall staffing levels were up “marginally,” suggesting some stabilization and return to levels from before the COVID-19 pandemic, according to a report from the American Medical Group Association.

Investigators assessed integration of mGPS for risk stratification based on data from the phase 3 IMmotion151 study and the phase 2 IMmotion150 study.

Recent advances in technology make it possible to access and harness the vast amounts of clinical data EHRs have produced.

"About 29% of our high-risk patients tested AI biomarker negative, and they could thus be spared the long-term [adverse] effects of ADT for 2 to 3 years," says Andrew J. Armstrong, MD, MSc.